Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Dose-Escalation Study of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma
jRCT2080221904Phase 1
- Sponsor
- AstraZeneca
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of azd1208 in Non-hematologic malignancy and lymphosarcoma, sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of AZD1208, Maximum tolerated dose (MTD) of AZD1208 and 1 more.
02
Drugs
azd1208
03
Conditions
Non-hematologic malignancylymphosarcoma
Beyond the preview
Go deeper on jRCT2080221904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221904.